PTGS2 and prostate carcinoma: Analysis of data from the Radiation Therapy Oncology Group (RTOG)-9202 trial which randomized men with prostate cancer to short or long term androgen-deprivation therapy, demonstrated that COX-2 expression was associated with biochemical failure and distant metastasis [48].